Brian O Mahony/ X
Jul 12, 2026, 06:45
Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
“First day of ISTH 2026 in sweltering Paris.
Trakymiene on Phase 3 data Concuzimab proplylaxis in PWH with inhibitors. 45 children.
ABR v on -demand decreased from 11.5-2 ( no surprise. On -demand always high ABR-ideally new therapies should compare with previous prophylaxis)”
Find more posts featuring Brian O Mahony on Hemostasis Today.
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology
-
Jul 11, 2026, 23:36Emmanuel J Favaloro: A Fresh Perspective on the Manual Tilt Tube Method for PT and INR Determination
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research